The U.S. Supreme Court ruling that drug manufacturers' federally approved labeling does not protect them from state lawsuits should not raise insurance rates for pharmaceutical companies, according to one brokerage expert.
James Walters, managing director of Aon's life science industry practice in Philadelphia, said the ruling should not impact rates because historically the sector has had no protection.
In the case that went before the Supreme Court, Wyeth pharmaceutical had argued that an implied protection existed for drug labeling approved by the Food and Drug Administration and this preempted state tort law permitting suits for failing to adequately warn consumers.
Recommended For You
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more inforrmation visit Asset & Logo Licensing.
